FCS Physicians Address Community Oncology Alliance National Briefing
WASHINGTON, D.C. – February 12, 2018. . . . . . . . .On Wednesday, February 7th, the Community Oncology Alliance (COA) hosted a “State of the Union” briefing at the National Press Club in Washington, DC on the current status of community oncology in the United States. Florida Cancer Specialists (FCS) physician leaders Dr. Michael Diaz and Dr. Lucio Gordan were two of the experts who presented to the more than 110 attendees, representing national cancer care, patient advocates, providers, and industry organizations.
Dr. Gordan spoke about Site of Care Analysis and the economics of cancer care, comparing the lower cost and other advantages of community oncology treatment tothe higher costs of hospital-based care. Dr. Diaz served on a panel discussion about the pressing issues and challenges to Community Oncology in the U.S., including political concerns, 340B reform, patient advocacy and the impact of Pharmacy Benefit Managers (PBMs) on cancer care, among others.
FCS CEO Bradley Prechtl, MBA, stated, “Florida Cancer Specialists is committed to supporting COA’s efforts to strengthen community oncology in the United States and advocate for patients. Many of our FCS physicians have served on COA’s various committees and boards, and as speakers at several COA conferences. We look forward to continuing our long-standing collaboration with the organization, furthering and promoting the community oncology model.”
Current FCS physicians providing board leadership to COA include Drs. Lucio Gordan (Gainesville), Robert Green (West Palm Beach) and Michael Diaz (St. Petersburg), who serves as COA Vice-President. Dr. Diaz also is on the Executive Committee and the Payment Reform Committee; Dr. Gordan serves on the COA Conference Committee and the Payment Reform Committee; Sarah Cevallos, Chief Revenue Cycle Officer at FCS, also is on the Payment Reform Committee.
Dr. William Harwin, Founder and President of FCS, added, “FCS will continue to support COAs mission and its specific goals for 2018, which include stopping regressive payment policies, including the Part B Experiment, continuing to expose abuses in the 340B drug discount program and Pharmacy Benefit Manager (PBM) intrusions. As one of the practices chosen to participate in the national Oncology Care Model (OCM), FCS will also continue our dedication to a value-based practice model that advances payment reform, while enhancing patient care.”
Florida Cancer Specialists will also have a strong presence at the 2018 Community Oncology Conference, which will be held in National Harbor, MD, just outside of Washington, DC, on April 12-13, 2018.
To view the COA “State of the Union” presentation:
# # #
About Florida Cancer Specialists & Research Institute: (FLCancer.com)
Founded in 1984, Florida Cancer Specialists & Research Institute (FCS) is the largest independent medical oncology/hematology practice in the United States. With over 200 physicians, more than 170 nurse practitioners and physician assistants and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings close to home.
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, FCS offers patients access to more clinical trials than any private oncology practice in Florida. 84% of new cancer drugs approved in 2016 for use in the U.S. were studied in clinical trials conducted with FCS participation*. Our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan-Kettering, the physicians of Florida Cancer Specialists provide leadership and consultation in the state's leading hospitals.
FCS serves patients on the Gulf Coast from Naples to the greater Tampa Bay area, north as far as Tallahassee, in Orlando and surrounding Central Florida communities, and on the East Coast from Jacksonville/Fleming Island to Palm Beach County.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research and cutting-edge technologies that help advance targeted treatments and genetically-based immunotherapies, and embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
* Prior to approval
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer - SGlenn@FLCancer.com